Market Place
Sourcing Support
Prelude Therapeutics Presents Phase 1 Results of PRT2527 Study
11 Dec 2024 //
GLOBENEWSWIRE
BeiGene Highlights Waldenström’s Macroglobulinemia At IWWM 2024
16 Oct 2024 //
BUSINESSWIRE
BeiGene Announces Updates to Commercial Leadership Team
09 Sep 2024 //
BUSINESSWIRE
BeiGene To Present BRUKINSA Plus Venetoclax CLL SLL Data
14 Jun 2024 //
BUSINESSWIRE
BeiGene & NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA
13 Jun 2024 //
BUSINESSWIRE
Glenmark unit ties up with BeiGene to market cancer drugs in India
21 May 2024 //
MONEYCONTROL
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia
13 Mar 2024 //
BUSINESSWIRE
US FDA approves expanded use of BeiGene`s blood cancer drug
08 Mar 2024 //
REUTERS
BeiGene Announces FDA Accelerated Approval of BRUKINSA
07 Mar 2024 //
BUSINESSWIRE
FDA Confirms Paragraph IV Patent Litigation for Zanubrutinib Capsules
10 Jan 2024 //
FDA
BeiGene`s Brukinsa (zanubrutinib) Receives Approval in Europe
13 Dec 2023 //
EMA
Singapore’s Drug List adds BeiGene`s Zanubrutinib for multiple indications
24 Nov 2023 //
BIOSPECTRUM ASIA
BeiGene Receives European Commission Approval for BRUKINSA
17 Nov 2023 //
BUSINESSWIRE
BeiGene touts Brukinsa data, Cellectis compares CAR-T to CDMO CAR-T
03 Nov 2023 //
ENDPTS
BRUKINSA® Receives Positive Recommendation from NICE in U.K.
20 Oct 2023 //
BUSINESSWIRE
BeiGene Receives Positive CHMP Opinion for BRUKINSA in Follicular Lymphoma
13 Oct 2023 //
BUSINESSWIRE
Zanubrutinib Sustains Response Vs Ibrutinib in Waldenström Macroglobulinemia
17 Aug 2023 //
ONCLIVE
FDA Accepts Zanubrutinib Application For New Follicular Lymphoma Indication
17 Jul 2023 //
PRESS RELEASE
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
12 Jul 2023 //
BUSINESSWIRE
Long-Term ROSEWOOD Data Confirm Efficacy of Zanubrutinib Plus
27 Jun 2023 //
ONCOLIVE
AbbVie`s Imbruvica-Brukinsa patent suit may have merit: expert
27 Jun 2023 //
FIERCE PHARMA
Zanubrutinib Plus Obinutuzumab and Venetoclax Induces High Undetectable MRD
22 Jun 2023 //
ONCLIVE
BeiGene Highlights Significant BRUKINSA Data at 17th International Conference
15 Jun 2023 //
PRESS RELEASE
BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
15 Jun 2023 //
BUSINESSWIRE
BeiGene offers free Brukinsa to patients in low-income countries
18 May 2023 //
FIERCE PHARMA
China’s NMPA approves BeiGene’s Brukinsa to treat WM, CLL/ SLL
08 May 2023 //
GLOBENEWSWIRE
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
07 May 2023 //
BUSINESSWIRE
BeiGene doubles sales on Brukinsa, tislelizumab strength
27 Feb 2023 //
FIERCE PHARMA
BeiGene`s Brukinsa (zanubrutinib) Approved In Europe
13 Feb 2023 //
EMA
BRUKINSA Receives Marketing Authorization for CLL & MZL in Great Britain by MHRA
19 Jan 2023 //
PRESS RELEASE
BeiGene granted US nod for Brukinsa in chronic lymphocytic leukaemia
19 Jan 2023 //
BUSINESSWIRE
BeiGene wants greater blending of mental health into cancer care
14 Dec 2022 //
FIERCEPHARMA
BeiGene`s Brukinsa shows PFS benefit of 35% over Imbruvica
14 Dec 2022 //
BUSINESSWIRE
BeiGene Receives European Commission Approval for BRUKINSA
17 Nov 2022 //
BUSINESSWIRE
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib)
02 Nov 2022 //
PRESS RELEASE
BeiGene gains further approvals for Brukinsa in Latin America
31 Oct 2022 //
THEPHARMALETTER
BeiGene Expands Reach of its Innovative BTK Inhibitr Recent Regulatory Approvals
26 Oct 2022 //
PRESS RELEASE
BeiGene touts Brukinsa-Imbruvica head-to-head win in CLL
13 Oct 2022 //
FIERCEPHARMA
UK NICE recommends zanubrutinib for Waldenstrom’s macroglobulinaemia
03 Oct 2022 //
PHARMACEUTICAL-TECHNOLOGY
NICE says yes to BeiGene’s Brukinsa after Scottish nay
21 Sep 2022 //
PHARMAPHORUM
NICE signs off on BeiGene`s Brukinsa for blood cancer disorder
20 Sep 2022 //
FIERCEPHARMA
NICE Recommends BeiGene’s BRUKINSA for Waldenström’s Macroglobulinemia
19 Sep 2022 //
BUSINESSWIRE
FDA extends BeiGene`s Brukinsa review in key leukemia realm
14 Jun 2022 //
FIERCEPHARMA
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
13 Jun 2022 //
BUSINESSWIRE
BeiGene Announces BRUKINSA Approval in Uruguay in MCL, MZL, and WM
28 Apr 2022 //
BUSINESSWIRE
BRUKINSA Demonstrates Superior ORR Vs Ibrutinib in Analysis of ALPINE Trial
11 Apr 2022 //
BUSINESSWIRE
BeiGene and Medison Announce Approval and National Reimbursement for BRUKINSA
15 Mar 2022 //
BUSINESSWIRE
BeiGene Ireland`s Brukinsa (zanubrutinib) Receives Approval in Europe
05 Mar 2022 //
EMA
BeiGene Announces Health Canada Approval for BRUKINSA in r/r MZL
03 Mar 2022 //
BUSINESSWIRE
FDA Accepts BeiGene`s sNDA for BRUKINSA (zanubrutinib) in CLL
22 Feb 2022 //
BUSINESSWIRE
BeiGene Announces Approval for BRUKINSA by Swissmedic for WM
17 Feb 2022 //
BUSINESSWIRE
Supplemental NDA accepted for leukaemia treatment in China
28 Jan 2022 //
PHARMAFILE
NMPA Accpets BeiGene`s sNDA for BRUKINSA in Waldenström’s Macroglobulinemia
20 Jan 2022 //
BUSINESSWIRE
BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL)
02 Dec 2021 //
PRESS RELEASE
BeiGene Announces Inclusion in the China National Reimbursement Drug List
02 Dec 2021 //
BUSINESSWIRE
Saudi FDA approves BeiGene & NewBridge Pharma’s Brukinsa to treat r/r MCL
16 Nov 2021 //
PHARMABIZ
BeiGene and NewBridge Pharma Announce Approval in Saudi Arabia of BRUKINSA®
13 Nov 2021 //
BUSINESSWIRE
BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia
04 Nov 2021 //
BUSINESSWIRE
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA®
20 Oct 2021 //
BUSINESSWIRE
